Get started
Author

Jason Caulfield

Observed institution: Autolus (United Kingdom)
ORCID: 0009-0005-0080-6594
Observed ORCID: 0009-0005-0080-6594
OpenAlex ID: A5140944569
CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al. · Cancer Research Communications · 1
Figure 2 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S3 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 5 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S5 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Data from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Figure S1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 3 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S6 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S2 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 4 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Supplementary Table S4 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Table 1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Figure 1 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study
2026 · Claire Roddie, William Day, et al.
Works count: 15
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type